N-(4-Heptyl-phenyl)-acrylamide | 20330-68-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-Heptyl-phenyl)-acrylamide
• 英文别名: N-(4-heptylphenyl)prop-2-enamide
• CAS: 20330-68-1
• 化学式: C₁₆H₂₃NO
• 分子量: 245.365
• InChiKey: NAOLFESCLOUACU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(4-Heptyl-phenyl)-acrylamide 在 palladium diacetate 、 TEA 、 ammonium acetate 、 溶剂黄146 、 三(邻甲基苯基)磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 (E)-3-[4-(5-{4-[(E)-2-(4-heptyl-phenylcarbamoyl)-vinyl]phenyl}-1H-imidazol-4-yl)-phenyl]acrylic acid tert-butyl ester
  参考文献：
  名称：

  Development of Potent Non-Carbohydrate Imidazole-Based Small Molecule Selectin Inhibitors with Antiinflammatory Activity

  摘要：

  A novel series of non-carbohydrate imidazole-based selectin inhibitors has been discovered via high-throughput screening using a P-selectin ELISA-based assay system. The initial lead 1 had an IC(50) of 17 muM in the P-selectin ELISA; this potency was significantly improved via an extensive SAR exploration. One of the current lead compounds (29) has an IC(50) of 300 nM in a P-selectin ELISA; it also has good activity in P- and E-selectin cell adhesion assays and shows efficacy in vivo. These compounds represent a novel series of sLe(X) mimetics with antiinflammatory activity. Their unique profile supports our interest in their further evaluation as drug candidates for the treatment of inflammation. Herein we describe the syntheses, optimization, and SAR of this series of novel potent selectin antagonists.

  DOI：

  10.1021/jm000508c
• 作为产物：
  描述：

  4-庚基苯胺 、 丙烯酰氯 在 TEA 作用下， 以 二氯甲烷 为溶剂， 生成 N-(4-Heptyl-phenyl)-acrylamide
  参考文献：
  名称：

  Development of Potent Non-Carbohydrate Imidazole-Based Small Molecule Selectin Inhibitors with Antiinflammatory Activity

  摘要：

  A novel series of non-carbohydrate imidazole-based selectin inhibitors has been discovered via high-throughput screening using a P-selectin ELISA-based assay system. The initial lead 1 had an IC(50) of 17 muM in the P-selectin ELISA; this potency was significantly improved via an extensive SAR exploration. One of the current lead compounds (29) has an IC(50) of 300 nM in a P-selectin ELISA; it also has good activity in P- and E-selectin cell adhesion assays and shows efficacy in vivo. These compounds represent a novel series of sLe(X) mimetics with antiinflammatory activity. Their unique profile supports our interest in their further evaluation as drug candidates for the treatment of inflammation. Herein we describe the syntheses, optimization, and SAR of this series of novel potent selectin antagonists.

  DOI：

  10.1021/jm000508c

文献信息

• Polymerizable polar compound, liquid crystal composition and liquid crystal display device
  申请人：JNC CORPORATION

  公开号：US10662379B2

  公开（公告）日：2020-05-26

  Shown is a compound represented by formula (1). For example, R1 is alkyl having 1 to 15 carbons; MES is a mesogen group having at least one ring; Sp1 is a single bond or alkylene having 1 to 10 carbons; M1 is methyl; and R2, M2 and M3 are hydrogen.

  所示为式（1）代表的化合物。例如，R1 是具有 1 至 15 个碳原子的烷基；MES 是具有至少一个环的中间基；Sp1 是单键或具有 1 至 10 个碳原子的亚烷基；M1 是甲基；R2、M2 和 M3 是氢。
• POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE
  申请人：JNC CORPORATION

  公开号：US20180195005A1

  公开（公告）日：2018-07-12

  Shown is a compound represented by formula (1). For example, R 1 is alkyl having 1 to 15 carbons; MES is a mesogen group having at least one ring; Sp 1 is a single bond or alkylene having 1 to 10 carbons; M 1 is methyl; and R 2 , M 2 and M 3 are hydrogen.
• LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT
  申请人：JNC CORPORATION

  公开号：US20210214615A1

  公开（公告）日：2021-07-15

  The liquid crystal display device of the disclosure has: a first substrate; a plurality of pixel electrodes formed on the first substrate; a second substrate; a counter electrode formed on the second substrate and facing the pixel electrode; a liquid crystal layer including a liquid crystal composition between the pixel electrode and the counter electrode; and an alignment control layer formed of a polymer containing an alignable monomer that is one component of the liquid crystal composition, in which the alignment control layers are each formed on a side of the first substrate and on a side of the second substrate. The alignable monomer is a polymerizable polar compound having a mesogen moiety formed of at least one ring, and a polar group.
• [EN] LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE<br/>[FR] ÉLÉMENT D'AFFICHAGE ET DISPOSITIF D'AFFICHAGE À CRISTAUX LIQUIDES<br/>[JA] 液晶表示素子、表示装置
  申请人：JNC CORP

  公开号：WO2018025974A1

  公开（公告）日：2018-02-08

  本発明は、素子を使用できる広い温度範囲、短い応答時間、高い電圧保持率、低いしきい値電圧、大きなコントラスト比、長い寿命のような特性を有する液晶表示素子である。本発明の液晶表示素子は、第１の基板と；前記第１の基板に形成された複数の画素電極と；第２の基板と；前記第２の基板に形成された、前記画素電極に対向する対向電極と；前記画素電極と前記対向電極の間の、液晶組成物を含有する液晶層と；前記液晶組成物の一成分である配向性モノマーを含む重合体により形成された配向制御層であって、前記第１の基板側および前記第２の基板側にそれぞれ形成された配向制御層と；を備える。前記配向性モノマーは、少なくとも１つの環より構成されたメソゲン部位と極性基とを有する重合性極性化合物であるため、本発明の液晶表示素子は、配向膜を形成することなく配向制御層により液晶組成物中の液晶性化合物を垂直配向させることができる。
• Development of Potent Non-Carbohydrate Imidazole-Based Small Molecule Selectin Inhibitors with Antiinflammatory Activity
  作者：Deborah H. Slee、Suzanne J. Romano、Jinghua Yu、Truc N. Nguyen、Judy K. John、Neil K. Raheja、Frank U. Axe、Todd K. Jones、William C. Ripka

  DOI：10.1021/jm000508c

  日期：2001.6.1

  A novel series of non-carbohydrate imidazole-based selectin inhibitors has been discovered via high-throughput screening using a P-selectin ELISA-based assay system. The initial lead 1 had an IC(50) of 17 muM in the P-selectin ELISA; this potency was significantly improved via an extensive SAR exploration. One of the current lead compounds (29) has an IC(50) of 300 nM in a P-selectin ELISA; it also has good activity in P- and E-selectin cell adhesion assays and shows efficacy in vivo. These compounds represent a novel series of sLe(X) mimetics with antiinflammatory activity. Their unique profile supports our interest in their further evaluation as drug candidates for the treatment of inflammation. Herein we describe the syntheses, optimization, and SAR of this series of novel potent selectin antagonists.